Crescent Grove Advisors’s Clorox CLX Stock Holding History

Crescent Grove Advisors’s Portfolio CLX Stock Details CLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,213	Closed	-$218K	–	273
2021 Q2	$218K	Buy	1,213 +113	+10%	+$20.6K	0.02%	239
2021 Q1	$212K	Buy	+1,100	New	+$212K	0.02%	194

Other funds holding CLX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CRC

Cedar Rock Capital London, United Kingdom $4.05B AUM 21.89% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Crescent Grove Advisors's CLX Position: Q3 2021 in Review

Crescent Grove Advisors sold out of Clorox (CLX) in Q3 2021, closing a stake of 1,213 shares — an estimated $218K sold.

Crescent Grove Advisors first reported a position in CLX in Q1 2021 and held it in 2 quarters. The position peaked at $218K in Q2 2021. 1,134 funds tracked by Wall St. Rank hold CLX as of Q3 2021.

Crescent Grove Advisors reported no remaining Clorox position as of Q3 2021 after selling out during the quarter.
Crescent Grove Advisors sold 1,213 Clorox shares in Q3 2021, an estimated $218K.
Crescent Grove Advisors first reported a position in Clorox in Q1 2021 and held it in 2 quarters.
Crescent Grove Advisors's Clorox position peaked at $218K in Q2 2021.
1,134 funds tracked by Wall St. Rank held Clorox as of Q3 2021.

Based on Crescent Grove Advisors's 13F filing for Q3 2021, filed 26 Oct 2021.